Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Iveric Bio Secures Key J-code for GA Therapy, Izervay
In a significant development for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), Iveric Bio, a subsidiary of Astellas Pharma, has been granted a unique, permanent J-code by the Centers for Medicare & Medicaid Services (CMS) for…
BlueRock and Foundation Fighting Blindness Partner for IRD Study
BlueRock Therapeutics LP, a clinical-stage cell therapy company and a subsidiary of Bayer, in partnership with Foundation Fighting Blindness, has announced their collaboration to introduce a new cohort to the Foundation’s ‘Uni-Rare natural history study’. This initiative focuses on individuals…
Scientists Create Enzyme-Activated Healing Contact Lenses
Scientists at the University of Waterloo have made a groundbreaking development in eye care technology by creating a new type of contact lens that not only serves as a protective bandage for corneal wounds but also delivers healing drugs in…
Gene Therapy Aims to Curtail Retinal Degeneration in RP
In a landmark study that promises new hope for nearly 1.5 million people worldwide suffering from retinitis pigmentosa (RP), scientists at Columbia University Vagelos College of Physicians and Surgeons are pioneering a gene therapy that could potentially treat RP patients…
Purdue Engineering Team to Develop Smart Contact Lenses
Research teams at Purdue University’s College of Engineering have been awarded two grants from the National Eye Institute, totaling an impressive $6.7 million. These funds are earmarked for the development of specialized smart soft contact lenses designed for the continuous monitoring…
Nicox Reveals Successful Phase 3 Glaucoma Eye Drop
Nicox SA announced the results of its pivotal Mont Blanc Phase 3 trial, which compared the efficacy of its novel nitric oxide-donating bimatoprost eye drop, NCX 470, against latanoprost in reducing intraocular pressure (IOP) in patients suffering from open-angle glaucoma…
Innovent’s nAMD Drug Succeeds in Phase 2 Trial
Innovent Biologics announced that its second Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a high-dose recombinant human VEGFR-Fc-Human CR1 fusion protein injection, has achieved its primary endpoint in treating Chinese subjects with neovascular age-related macular degeneration (nAMD).…
2023 Recap: Top 20 Ophthalmic Collaborations of the Year
As we bid farewell to 2023, it’s time to reflect on the remarkable collaborations that have shaped the landscape of ophthalmic innovation. The past year witnessed groundbreaking partnerships between pharmaceutical giants, tech innovators, and research institutions, all aimed at advancing…
Top 12 Gene Therapies for Eye Diseases and Blindness
In a groundbreaking era of medical research, scientists and clinicians are spearheading novel gene therapies that hold promise for transforming the landscape of eye disease treatment. These cutting-edge interventions address a spectrum of conditions ranging from Usher Syndrome and retinoschisis…
2023 Recap: Top 15 Ophthalmic Medical Devices
In a groundbreaking year for ophthalmic advancements, 2023 has witnessed the launch of cutting-edge medical devices that promise to reshape the landscape of eye care. From augmented reality headsets to innovative surgical systems, the field is experiencing a wave of…